18:23 , Feb 15, 2019 |  BC Week In Review  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
23:28 , Feb 14, 2019 |  BC Extra  |  Company News

Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and in-licensed exclusive European...
18:36 , Feb 8, 2019 |  BC Extra  |  Clinical News

uniQure gets bump on latest hemophilia readout

uniQure N.V. (NASDAQ:QURE) added $3.31 (10%) to $36.49 Friday after new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Monday...
00:28 , Feb 2, 2019 |  BC Extra  |  Company News

Deal filing: BMS added CVR late in Celgene negotiations

Celgene Corp. (NASDAQ:CELG) rejected multiple overtures from Bristol-Myers Squibb Co. (NYSE:BMY) and solicited a bid from another pharma before accepting BMS's takeout offer last month -- but not before BMS replaced some guaranteed money with...
22:35 , Jan 30, 2019 |  BC Extra  |  Financial News

Shanghai exchange's proposed innovation board includes preprofit option

The Shanghai Stock Exchange has released draft guidelines for a proposed science and technology innovation board on the exchange that could allow preprofit biopharma companies to list in mainland China. Companies would need to meet...
13:50 , Jan 29, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays; binding assays A peptide cleavage-based assay for detecting B. anthracis lethal factor could enable rapid diagnosis of anthrax infection. The micro-plate based assay involves detecting B. anthracis lethal factor by co-incubating plasma...
21:46 , Jan 17, 2019 |  BC Innovations  |  Finance

Public funding highlights

Public funding highlights Selected developments and initiatives in 4Q18 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer; gastrointestinal; inflammation

INDICATION: Breast cancer; colitis; asthma Mouse studies suggest inhibiting SPR could help treat colitis and asthma, and its biosynthetic product THB could help treat breast cancer. In a xenograft mouse model of breast cancer, THB...